TY - JOUR T1 - De novo Powered Air-Purifying Respirator Design and Fabrication for Pandemic Response JF - medRxiv DO - 10.1101/2021.03.25.21252076 SP - 2021.03.25.21252076 AU - Akshay Kothakonda AU - Lyla Atta AU - Deborah Plana AU - Ferrous Ward AU - Chris Davis AU - Avilash Cramer AU - Robert Moran AU - Jacob Freake AU - Enze Tian AU - Ofer Mazor AU - Pavel Gorelik AU - Christopher Van AU - Christopher Hansen AU - Helen Yang AU - Michael S. Sinha AU - Ju Li AU - Sherry H. Yu AU - Nicole R. LeBoeuf AU - Peter K. Sorger Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/29/2021.03.25.21252076.abstract N2 - The rapid spread of COVID-19 and disruption of normal supply chains resulted in severe shortages of personal protective equipment (PPE), particularly devices with few suppliers such as powered air-purifying respirators (PAPRs). A scarcity of information describing design and performance criteria represents a substantial barrier to new approaches to address these shortages. We sought to apply open-source product development to PAPRs to enable alternative sources of supply and further innovation. We describe the design, prototyping, validation, and user testing of locally manufactured, modular, PAPR components, including filter cartridges and blower units, developed by the Greater Boston Pandemic Fabrication Team (PanFab). Two designs, one with a fully custom-made filter and blower unit housing, and the other with commercially available variants (the “Custom” and “Commercial” designs respectively) were developed. Engineering performance of the prototypes was measured and safety validated using NIOSH-equivalent tests on apparatus available under pandemic conditions, at university laboratories. Feedback on designs was obtained from four individuals, including two clinicians working in an ambulatory clinical setting and two research technical staff for whom PAPR use is a standard part of occupational PPE. Respondents rated the PanFab Custom PAPR a 4 to 5 on a 5 Likert-scale 1) as compared to current PPE options, 2) for the sense of security with use in a clinical setting, and 3) for comfort. The three other versions of the designs (with a commercial blower unit, filter, or both) performed favorably, with survey responses consisting of scores ranging from 3-5. Engineering testing and clinical feedback demonstrate that the PanFab designs represents favorable alternative PAPRs in terms of user comfort, mobility, and sense of security. A nonrestrictive license promotes innovation in respiratory protection for current and future medical emergencies.Competing Interest StatementPKS is a member of the SAB or Board of Directors of Applied Biomath, Glencoe Software and RareCyte Inc and has equity in these companies; he is on the SAB of NanoString Inc. In the last five years the Sorger lab has received research funding from Novartis and Merck. PKS declares that none of these relationships are directly or indirectly related to the content of this manuscript. NRL is a consultant for or has received honoraria from the following companies: Seattle Genetics, Sanofi, and Bayer. CD, RM, and JF are employees of GenOne Technologies, Mine Survival, and Fikst Product Development, respectively.Funding StatementLocal citizens and engineers have generously donated their time and resources to PanFab and they are essential to program success. This work was supported by the MIT COVID-19 Emergency Fund, Harvard-MIT Center for Regulatory Science by NIH/NCI grants P30-CA006516, U54-CA225088 (to PKS, NL and DP) and by T32-GM007753 (to DP) and by the Harvard Ludwig Center. AKC is supported by the Hugh Hampton Young Fellowship of MIT.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Partners Healthcare Institutional Review Board declared that the study did not require ethical oversight (protocol #2021P000727).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll study materials and data are available in Supplementary Materials and through the online repository https://github.com/labsyspharm/PanFab-PAPR-2021. https://github.com/labsyspharm/PanFab-PAPR-2021 ER -